Effect of Premature Luteinizing Hormone Rise on Pregnancy Outcomes in Patients with High Trigger Day Progesterone Levels in GnRH Antagonist In Vitro Fertilization Cycles

İnce, Onur; Uçuran, Gönenç; Özvatan, Selviye Halksever; Özer, Mehmet; Duymus, Ayse Ceren; Demir, Mustafa; Köse, Can; Yılmaz, Bülent

doi:10.5336/gynobstet.2016-54409

Cited by 1 publication

(1 citation statement)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present study and two previous studies (7,8) , no premature luteinization was observed in any patient even though the GnRH antagonist implementation on the day of hCG was stopped. Moreover, the recent studies showed that the increasing level of progesterone did not decrease pregnancy rates (20,21) . For this reason, the results of the present study and those of previous studies suggest that the implementation of GnRH antagonist in stimulation in order to prevent possible negative effects that might develop due to the premature increase of LH deteriorates formation of mature oocyte and the dynamics of embryos’ development.…”

Section: Discussionmentioning

confidence: 97%

Cost-effectiveness of GnRH antagonist implementation on hCG injection day

Özdemir

Ayas

Güven

et al. 2019

tjod

View full text Add to dashboard Cite

Objective: To compare the outcomes of antagonist stimulation protocols and to compare the cost effectiveness. Materials and Methods: Between 2011 and December 2017, a total of 354 women who underwent intracytoplasmic sperm injection and controlled ovarian stimulation with antagonist protocols were enrolled in the study. The antagonist implementation on the day of human chorionic gonadotropin (hCG) was continued for 194 of women, whereas the antagonist was stopped 36 hours before in 160 women. The stimulation outcomes of patients and cost-effectiveness of the regimens were compared. Results: There was a significant difference between the groups in terms of number of cryopreserved embryos, mature/immature oocyte ratio, and embryo transfer cancellations (p<0.05). The median value for the mature/immature oocyte ratio was 1.1 (0.2-7.5) and 1 (0.5-15) (p=0.001), and the ET cancellation was 5.3% vs. 1% for group 1 and 2, respectively (p=0.037). There was no difference between the groups in terms of pregnancy rates (p=0.197). Conclusion: No difference was found in the clinical pregnancy rates between the two groups. For this reason, the cessation of antagonist implementation on the day of hCG seems more advantageous in terms of cost-effectiveness and fewer injections.

show abstract